EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In-Vitro Generation of T-Cell Clones to Difluorophenylglyoxal: Implications for Understanding the Immunogenicity of MK-3207

Paul Thomson iD, Andrew Gibson, Jackie Shang iD, Xiaoli Meng iD, Eleanor Saville, Sophie Grice iD, Megan Ford, Yu Feng iD, Kara Pearson, Michael Oropallo, Raymond Gonzalez, James Monroe und 1 weitere

Chemical Research in Toxicology · 17.08.2026 · 39 (8) · 1503-1507

DOI: 10.1021/acs.chemrestox.6c00294 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemical Research in Toxicology, online erschienen am 30.07.2026. Verfasst von Paul Thomson und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department Pharmacology and Therapeutics, University of Liverpool, LiverpoolL693GE, U.K. Hauptthemen laut MEDLINE: T-Lymphocytes. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

MK-3207 was withdrawn from development because of drug-induced liver injury. Metabolic studies identified bioactivation to a protein-reactive 3,5-difluorophenylglyoxal (DFPG) intermediate. Although phenylglyoxal metabolites readily form protein adducts, their immunogenic potential has been poorly understood. We compared the immunogenicity of three DFPG isomers (3,5-, 2,4-, and 3,4-DFPG) using T-cell clones generated from treated healthy donor PBMCs. Reactive clones were detected against isomers with 3,5-DFPG inducing the strongest responses. Activation required antigen processing, and no cross-reactivity with MK-3207 was observed. These findings demonstrate the immunogenicity of 3,5-DFPG and show that structural differences among phenylglyoxal isomers influence T cell activation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

T-LymphocytesHumansLymphocyte Activation

Autor:innen und Institutionen

  • Department Pharmacology and Therapeutics, University of Liverpool, LiverpoolL693GE, U.K.
  • Institute for Immunology and Infectious Diseases, Murdoch University, MurdochWA6150, Australia.
  • Investigative Toxicology, Nonclinical Drug Safety, Merck & Co., West Point, Pennsylvania19486, United States.

ORCID-Profile: Paul Thomson, Jackie Shang, Xiaoli Meng, Sophie Grice, Yu Feng, Dean Naisbitt

Förderung

  • Merck

Zitieren

APA

Thomson, P., Gibson, A., Shang, J., Meng, X., Saville, E., Grice, S., Ford, M., Feng, Y., Pearson, K., Oropallo, M., Gonzalez, R., Monroe, J., & Naisbitt, D. (2026). In-Vitro Generation of T-Cell Clones to Difluorophenylglyoxal: Implications for Understanding the Immunogenicity of MK-3207. Chemical Research in Toxicology, 39(8), 1503-1507. https://doi.org/10.1021/acs.chemrestox.6c00294

Vancouver

Thomson P, Gibson A, Shang J, Meng X, Saville E, Grice S, et al. In-Vitro Generation of T-Cell Clones to Difluorophenylglyoxal: Implications for Understanding the Immunogenicity of MK-3207. Chemical Research in Toxicology. 2026;39(8):1503-1507. doi:10.1021/acs.chemrestox.6c00294

BibTeX
@article{Thomson2026,
  author = {Thomson, Paul and Gibson, Andrew and Shang, Jackie and Meng, Xiaoli and Saville, Eleanor and Grice, Sophie and Ford, Megan and Feng, Yu and Pearson, Kara and Oropallo, Michael and Gonzalez, Raymond and Monroe, James and Naisbitt, Dean},
  title = {In-Vitro Generation of T-Cell Clones to Difluorophenylglyoxal: Implications for Understanding the Immunogenicity of MK-3207},
  journal = {Chemical Research in Toxicology},
  year = {2026},
  volume = {39},
  number = {8},
  pages = {1503--1507},
  doi = {10.1021/acs.chemrestox.6c00294}
}
Kostenlos starten →